Azacitidine Plus Amifostine in Treating Patients With Myelodysplastic Syndrome

Completed · Phase 2

Conditions studied: Myelodysplastic Syndromes

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Amifostine may improve blood counts in patients with myelodysplastic syndrome. Combining azacitidine with amifostine may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of azacitidine plus amifostine in treating patients who have myelodysplastic syndrome.

Key facts

Study ID

NCT00005598

Run by

University of Michigan Rogel Cancer Center

Starts

2000-10-01

Expected to finish

2002-03-01

Last updated by the study team

2012-12-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.